Silencing of EphA2 inhibits invasion of human gastric cancer SGC-7901 cells in vitro and in vivo

Neoplasma

Volumn 59, Issue 1, 2012, Pages 105-113

  Yuan, W ^a   Chen, Z ^a   Wu, S ^a   Guo, J ^b   Ge, J ^a   Yang, P ^a   Huang, J ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b Yiyang Central Hospital   (China)

Author keywords

EphA2; Gastric cancer; MMP 9; SGC 7901; siRNA; Tumor invasion

Indexed keywords

EPHRIN RECEPTOR A2; GELATINASE B; LIPOSOME; SMALL INTERFERING RNA; TUMOR PROTEIN;

ANIMAL TISSUE; ARTICLE; CANCER PROGNOSIS; CELL CYCLE ARREST; CELL INVASION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; GENE EXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; METASTASIS; MOUSE; NONHUMAN; PLASMID; POLYACRYLAMIDE GEL ELECTROPHORESIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; STOMACH CANCER; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING; ADENOCARCINOMA; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; CANCER INVASION; CELL CYCLE; CELL DIVISION; DOWN REGULATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; ENZYME INDUCTION; GENE THERAPY; GENE VECTOR; GENETICS; MOLECULARLY TARGETED THERAPY; NUDE MOUSE; PATHOLOGY; PHYSIOLOGY; RANDOMIZATION; STOMACH TUMOR; TRANSPLANTATION; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; CELL CYCLE; CELL DIVISION; CELL LINE, TUMOR; DOWN-REGULATION; ENZYME INDUCTION; GENE THERAPY; GENETIC VECTORS; HUMANS; LIPOSOMES; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED BALB C; MICE, NUDE; MOLECULAR TARGETED THERAPY; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; RANDOM ALLOCATION; RECEPTOR, EPHA2; RNA INTERFERENCE; RNA, SMALL INTERFERING; STOMACH NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84863748989     PISSN: 00282685     EISSN: 13384317     Source Type: Journal    
DOI: 10.4149/neo_2012_014     Document Type: Article

References (27)

1. AMIT I, WIDES R, YARDEN Y Evolvable signaling networks of receptor tyrosine kinases: relevance of robustness to malignancy and to cancer therapy. Mol Syst Biol 2007; 3: 151. http://dx.doi.org/10.1038/msb4100195
2. SULMAN EP, TANG XX, ALLEN C, BIEGEL JA, PLEASURE DE et al. a human EPH-related gene, maps to 1p36.1, a com mon region of alteration in human cancers. Genomics 1997; 40: 371-374. http://dx.doi.org/10.1006/geno.1996.4569
3. WANG LF, FOKAS E, BIEKER M, ROSE F, REXIN P et al. Increased expression of EphA2 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients. Oncol Rep 2008; 19: 151-156.
4. BRANNAN JM, DONG W, PRUDKIN L, BEHRENS C, LOTAN R et al. Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non-small cell lung cancer. Clin Cancer Res 2009; 15: 4423-4430. http://dx.doi.org/10.1158/1078-0432.CCR-09-0473
5. CUI XD, LEE MJ, YU GR, KIM IH, YU HC et al. EFNA1 ligand and its receptor EphA2: potential biomarkers for hepatocellular carcinoma. Int J Cancer 2010; 126: 940-949. http://dx.doi.org/10.1002/ijc.24798
6. BAETEN CI, HILLEN F, PAUWELS P, DE BRUINE AP, BAETEN CG Prognostic role of vasculogenic mimicry in colorectal cancer. Dis Colon Rectum 2009; 52: 2028-2035. http://dx.doi.org/10.1007/DCR.0b013e3181beb4ff
7. MERRITT WM, KAMAT AA, HWANG JY, BOTTSFORDMILLER J, LU C et al. Clinical and biological impact of EphA2 overexpression and angiogenesis in endometrial cancer. Cancer Biol Ther 2011; 10: 1306-1314. http://dx.doi. org/10.4161/cbt.10.12.13582
8. YUAN WJ, GE J, CHEN ZK, WU SB, SHEN H et al. Overexpression of EphA2 and EphrinA-1 in human gastric adenocarcinoma and its prognostic value for postoperative patients. Dig Dis Sci 2009; 54: 2410-2417. http://dx.doi. org/10.1007/s10620-008-0649-4
9. LU C, SHAHZAD MM, WANG H, LANDEN CN, KIM SW et al. EphA2 overexpression promotes ovarian cancer growth. Cancer Biol Ther 2008; 7: 1098-1103. http://dx.doi. org/10.4161/cbt.7.7.6168
10. ROY R, YANG J, MOSES MA Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol 2009; 27: 5287-5297. http://dx.doi. org/10.1200/JCO.2009.23.5556
11. LINN R, DUPONT BR, KNIGHT CB, PLAETKE R, LEACH RJ Reassignment of the 92-kDa type IV collagenase gene (CLG4B) to human chromosome 20. Cytogenet Cell Genet 1996; 72: 159-161. http://dx.doi.org/10.1159/000134175
12. LEE LY, WU CM, WANG CC, YU JS, LIANG Y et al. Expression of matrix metalloproteinases MMP-2 and MMP-9 in gastric cancer and their relation to claudin-4 expression. Histol Histopathol 2008; 23: 515-521.
13. GAO ZL, ZHANG C, DU GY, LU ZJ Clinical significance of changes in tumor markers, extracellular matrix, MMP-9 and VEGF in patients with gastric carcinoma. Hepatogastroenterology 2007; 54: 1591-1595.
14. DERYUGINA EI, QUIGLEY JP Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev 2006; 25: 9-34. http://dx.doi.org/10.1007/s10555-006-7886-9
15. YANG P, YUAN W, HE J, WANG J, YU L et al. Overexpression of EphA2, MMP-9, and MVD-CD34 in hepatocellular carcinoma: Implications for tumor progression and prognosis. Hepatol Res 2009; 39: 1169-1177. http://dx.doi.org/10.1111/j.1872-034X.2009.00563.x
16. DUXBURY MS, ITO H, ZINNER MJ, ASHLEY SW, WHANG EE EphA2: a determinant of malignant cellular behavior and a potential therapeutic target in pancreatic adenocarcinoma. Oncogene 2004; 23: 1448-1456. http://dx.doi.org/10.1038/sj.onc.1207247
17. LANDEN CN JR, CHAVEZ-REYES A, BUCANA C, SCHMANDT R, DEAVERS MT et al. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 2005; 65: 6910-6918. http://dx.doi. org/10.1158/0008-5472.CAN-05-0530
18. LANDEN CN, MERRITT WM, MANGALA LS, SANGUINO AM, BUCANA C et al. Intraperitoneal delivery of liposomal siRNA for therapy of advanced ovarian cancer. Cancer Biol Ther 2006; 5: 1708-1713. http://dx.doi.org/10.4161/cbt.5.12.3468
19. NASREEN N, MOHAMMED KA, ANTONY VB Silencing the receptor EphA2 suppresses the growth and haptotaxis of malignant mesothelioma cells. Cancer 2006; 107: 2425-2435. http://dx.doi.org/10.1002/cncr.22254
20. ZHOU Z, YUAN X, LI Z, TU H, LI D et al. RNA interference targeting EphA2 inhibits proliferation, induces apoptosis, and cooperates with cytotoxic drugs in human glioma cells. Surg Neurol 2008; 70: 562-569. http://dx.doi.org/10.1016/j.surneu.2008.04.031
21. TADDEI ML, PARRI M, ANGELUCCI A, BIANCHINI F, MARCONI C et al. EphA2 induces metastatic growth regulating amoeboid motility and clonogenic potential in prostate carcinoma cells. Mol Cancer Res 2011; 9: 149-160 http://dx.doi.org/10.1158/1541-7786.MCR-10-0298
22. Miao H, LI DQ, MUKHERJEE A, GUO H, PETTY A et al. EphA2 mediates ligand-dependent inhibition and ligandindependent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt. Cancer Cell 2009; 16: 9-20. http://dx.doi.org/10.1016/j.ccr.2009.04.009
23. LIN YG, HAN LY, KAMAT AA, MERRITT WM, LANDEN CN et al. EphA2 overexpression is associated with angiogenesis in ovarian cancer. Cancer 2007; 109: 332-340. http://dx.doi.org/10.1002/cncr.22415
24. DUXBURY MS, ITO H, ZINNER MJ, ASHLEY SW, WHANG EE Ligation of EphA2 by Ephrin A1-Fc inhibits pancreatic adenocarcinoma cellular invasiveness. Biochem Biophys Res Commun 2004; 320: 1096-1102. http://dx.doi.org/10.1016/j.bbrc.2004.06.054
25. CHEN LX, HE YJ, ZHAO SZ, WU JG, WANG JT et al. Inhibition of tumor growth and vasculogenic mimicry by curcumin through down-regulation of the EphA2/PI3K/MMP pathway in a murine choroidal melanoma model. Cancer Biol Ther 2011; 11: 229-235. http://dx.doi.org/10.4161/cbt.11.2.13842
26. WYKOSKY J, DEBINSKI W The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting. Mol Cancer Res 2008; 6: 1795-1806. http://dx.doi. org/10.1158/1541-7786.MCR-08-0244
27. CHAKRABORTI S, MANDAL M, DAS S, MANDAL A, CHAKRABORTI T Regulation of matrix metalloproteinases: an overview. Mol Cell Biochem 2003; 253: 269-285. http://dx.doi.org/10.1023/A:1026028303196